Background Information
Lymphoma is the most common malignancy affecting dogs, accounting for approximately 20 % of all canine tumours. It can be seen in any dog, although some breeds show a particularly high incidence including Golden Retrievers, Boxers, German Shepherds and Terriers, and presentation is more likely to occur beyond middle age. It is well established that lymphoma is one of the more treatable cancers and that the sooner the diagnosis can be made and treatment started, the more successful will be the outcome.
The PetScreen Canine Lymphoma Test employs advanced technology to detect lymphoma biomarkers present in a patient’s serum. Detection of these biomarkers indicates a high likelihood that the patient has lymphoma. The PetScreen CLT provides a minimally invasive alternative to a fine needle aspirate as a precursor to histological diagnosis of the disease.
The Canine Lymphoma Test should be used when a patient is suspected of having lymphoma by showing classical symptoms such as generalized lymphadenopathy, PU/PD and lethargy. Increasingly, the test is also showing great promise as a treatment monitoring tool.
In summary, the test provides:
- Simple blood test requiring only 1 ml of blood – taken as part of existing biochemistry/ haematology work up.
- A minimally invasive procedure.
- An alternative to taking an FNA sample and the associated risks of failing to retrieve sufficient lymphoid cells or encountering poor preservation of the cells
- A monitoring tool to assess treatment progression and to detect recurrence.
The PetScreen Lymphoma blood test requires the serum from a 1 ml blood sample. Two turnaround times are available, either 48 hours from receipt of sample or a reduced cost option with a 5 day turnaround time for less urgent cases.
Please contact PetScreen for individual pricing and price bundles for patient monitoring.
Back...
